

PATENT Attorney Docket No. LEX-003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):

Gillies et al.

SERIAL NO.:

10/256,156

GROUP NO.:

1647

FILING DATE:

February 24, 1999

EXAMINER:

Hunnicutt, Rachel Kapust

TITLE:

Enhancing the Circulating Half Life of Antibody Based Fusion Proteins

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

01

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the non-U.S. patent documents and non-patent publications are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

	(1)	within three (3) months of the filing date of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. 1.114; or
	(2)	after the period defined in (1) above but before the mailing date of any of a final action under 37 C.F.R. 1.113, a notice of allowance under 37 C.F.R. 1.311, or an action that otherwise closes prosecution in the application, and
		the requisite Statement is below, OR
	\boxtimes	the requisite fee under 37 C.F.R. 1.17(p), namely \$180.00, is included herein; or
04/01/2005 MWULDGE	1 00000029 09	256156
01 FC:1806		160.00 RP

Supplemental Information Disclosure Statement
Serial No. 09/256,156
Page 2 of 2

(3) after the period defined in (2) above but before the payment of the issue fee, AND

the requisite Statement is below, AND

the requisite petition fee under 37 C.F.R. 1.17(p), namely \$180.00 is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form

PTO-1449, and other information contained herein, be made of record in this application.

Respectfully submitted,

Respectfully submitted,

March 30, 2005

Reg. No. 48,645

Tel. No.: (617) 261-3169 Fax No.: (617) 261-3175 Brian A. Fairchild

Attorney for the Applicants Kirkpatrick & Lockhart Nicholson

Graham LLP 75 State Street

Boston, Massachusetts 02109-1808

BOS-823554 v1

PAGE 1 OF 12

PORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE

STATEMENT

ATTORNEY DOCKET NO.: LEX-003

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/256,156

FILING DATE: February 24, 1999

GROUP: 1647

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF	
							APPROPRIATE	
	A111	4,522,811	6/1/85	Eppstein et al.				
	A112	4,667,016	5/19/87	Lai et al.				
	A113	4,732,683	3/22/88	Georgiades et al.				
	A114	4,737,462	4/12/88	Mark et al.				
	A115	4,975,369	12/4/90	Beavers et al.				
	A116	5,082,658	1/21/92	Palladino				
	A117	5,091,513	2/25/92	Huston et al.				
	A118	5,399,346	3/21/95	Anderson et al.				
	A119	5,428,130	6/27/95	Capon et al.				
	A120	5,480,981	1/2/96	Goodwin et al.				
	A121	5,589,466	12/31/96	Felgner et al.		-		
	A122	5,614,184	3/25/97	Sytkowski et al.				
	A123	5,712,120	1/27/98	Rodriguez et al.				
	A124	5,738,852	4/14/98	Robinson et al.				
	A125	5,795,779	8/18/98	McCormick				
	A126	5,827,703	10/27/98	Debs et al.				
	A127	5,837,821	11/17/98	Wu et al.				
• •	A128	5,888,773	3/30/99	Jost et al.				
	A129	6,281,010	8/28/01	Gao et al.				
	A130	6,291,158	9/18/01	Winter et al.				
	A131	6,627,615	9/30/03	Debs et al.				
	A132	2004/0180035	9/16/04	Gillies et al.				

F	XAMINER	DATE CONSIDERED

PAGE 2 OF 12

FORM PTO - 1449

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-003

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/256,156

FILING DATE: February 24, 1999 GROUP: 1647

FOREIGN PATENT DOCUMENTS

EXAM INIT.		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
	B108	0 428 267 B1	12/11/96	EP					Y
	B109	0 428 596 B1	4/17/96	EP		Ì		· · · · · · · · · · · · · · · · · · ·	Y
	B110	0 433 827 B1	3/4/98	EP				<u>-</u> .	Y
	B111	0 519 596 A1	12/23/92	EP	-				Y
	B112	0 668 351 B1	9/22/99	EP					Y
	B113	0 699 755 A2	3/6/96	EP					Y
.	B114	2 188 638	10/7/87	GB					Y
	B115	WO 92/10755	6/25/92	PCT	-				Y
	B116	WO 94/25609	11/10/94	PCT				•	Y
	B117	WO 96/40792	12/19/96	РСТ					Y
	B118	WO 98/52976	11/26/98	РСТ					Y
	B119	WO 00/01822	1/13/00	РСТ					Y
	B120	WO 02/074783	9/26/02	РСТ					Y

EXAMINER	DATE CONSIDERED

PAGE 3 OF 12

FORM PTO - 1449

SUPPLEMENTAL INFORMATION DISCLOSURE **STATEMENT**

ATTORNEY DOCKET NO.: LEX-003

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/256,156

FILING DATE: February 24, 1999 GROUP: 1647

	OTHER ART, JOURNAL ARTICLES, ETC.						
EXAM. INIT.	ОТН	ER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)					
	C260	Aichele et al., (1994), "Peptide-Induced T-Cell Tolerance to Prevent Autoimmune Diabetes in a Transgenic Mouse Model," Proc. Natl. Acad. Sci. USA, 91:444-448.					
	C261	Altschul et al., (1990), "Basic Local Alignment Search Tool," J. Mol. Biol., 215:403-10.					
	C262	Altschul et al., (1997), "Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs," Nucleic Acids Res., 25(17):3389-3402.					
	C263	Anderson et al., (1980), "Characterization of the Fc Receptor for IgG on a Human Macrophage Cell Line U937," J. Immunol., 125(6):2735-41.					
	C264	Anderson et al., (1994), "Effects of Route and Formulation on Clinical Pharmacokinetics of Interleukin-2," Clin. Pharmacokinet., 27(1):19-31.					
	C265	Baici et al., (1980), "Kinetics of the Different Susceptibilities of the Four Human Immunoglobulin G Subclasses to Proteolysis by Human Lysosomal Elastase," <u>Scand. J. Immunol.</u> 12(1):41-50.					
1	C266	Barbulescu <i>et al.</i> , (1998), "IL-12 and IL-18 Differentially Regulate the Transcriptional Activity of the Human IFN-γ Promoter in Primary CD4+ T Lymphocytes," J. Immunol., 160:3642-7.					
	C267	Bednarek et al., (1991), "Soluble HLA-A2.1 Restricted Peptides that are Recognized by Influenza Virus Specific Cytotoxic T Lymphocytes," J. Immunol. Methods, 139:41-47.					
	C268	Benacerraf <i>et al.</i> , (1959), "The Clearance of Antigen Antibody Complexes from the Blood by the Reticulo-Endothelial System," J. Immunol., 82:131-7.					
	C269	Böhm, (1994), "On the Use of LUDI to Search the Fine Chemicals Directory for Ligands of Proteins of Known Three-Dimensional Structure," <u>J. Comput. Aided Mol. Des.</u> , 8:623-32.					
	C270	Böhm, (1994), "The Development of a Simple Empirical Scoring Function to Estimate the Binding Constant for a Protein-Ligand Complex of Known Three-Dimensional Structure," <u>J. Comput. Aided Mol. Des.</u> , 8(3):243-56.					
	C271	Böhm, (1998), "Prediction of Binding Constants of Protein Ligands: A Fast Method for the Prioritization of Hits Obtained from De Novo Design or 3D Database Search Programs," J. Comput. Aided Mol. Des., 12(4):309-23.					
	C272	Boshart et al., (1985), "A Very Strong Enhancer is Located Upstream of an Immediate Early Gene of Human Cytomegalovirus," Cell, 41:521-530.					
-	C273	Boulianne et al., (1984), "Production of Functional Chimaeric Mouse/Human Antibody," Nature, 312:643-6.					
	C274	Bourgois <i>et al.</i> , (1974), "Determination of the Primary Structure of a Mouse IgG2a Immunoglobulin: Amino-Acid Sequence of the Fc Fragment: Implications for the Evolution of Immunoglobulin Structure and Function," <u>Eur. J. Biochem.</u> , 43:423-35.					
	C275	Brambell <i>et al.</i> , (1964), "A Theoretical Model of γ-Globulin Catabolism," Nature, 203:1352-55.					
	C276	Brazolot Millan et al., (1998), "Cpg DNA Can Induce Strong TH1 Humoral and Cell-Mediated Immune Responses against Hepatitis B Surface Antigen in Young Mice," Proc. Natl. Acad. Sci. USA, 95:15553-8.					

EX.	٩M	INER	

ATTORNEY DOCKET NO.: LEX-003 **FORM PTO - 1449** APPLICANT(S): Gillies et al. SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT SERIAL NO.: 09/256,156 FILING DATE: February 24, 1999 **GROUP: 1647** OTHER ART, JOURNAL ARTICLES, ETC. EXAM. OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) INIT. Brekke et al., (1994), "Human IgG Isotype-Specific Amino Acid Residues Affecting Complement-Mediated C277 Cell Lysis and Phagocytosis," Eur. J. Immunol., 24:2542-2547. Brem et al., (1993), "The Combination of Antiangiogenic Agents to Inhibit Primary Tumor Growth and C278 Metastasis," J. Pediatr. Surg., 28(10):1253-7. Brooks et al., (1983), "CHARMM: A Program for Macromolecular Energy, Minimization, and Dynamics C279 Calculations," J. Comput. Chemistry, 4:187–217. Broudy et al., (1988), "Recombinant Human Erythropoietin: Purification and Analysis of Carbohydrate C280 Linkage," Arch. Biochem. Biophys., 265:329-36. Bubenik et al., (1995), "Interleukin-2 Gene Therapy of Residual EL-4 Leukaemia Potentiates the Effect of C281 Cyclophosphamide Pretreatment," J. Cancer Res. Clin. Oncol., 121:39-43. Bumol et al., (1982), "Unique Glycoprotein-Proteoglycan Complex Defined by Monoclonal Antibody on C282 Human Melanoma Cells," Proc. Natl. Acad. Sci. USA, 79:1245-9. Carnemolla et al., (1989), "A Tumor-Associated Fibronectin Isoform Generated by Alternative Splicing of C283 Messenger RNA Precursors," J. Cell. Biol., 108:1139-1148. Carnemolla et al., (1992), "The Inclusion of the Type III Repeat ED-B in the Fibronectin Molecule Generates C284 Conformational Modifications that Unmask a Cryptic Sequence," J. Biol. Chem., 267(34):24689-24692. Cazzola et al., (1998), "Red Blood Cell Precursor Mass as an Independent Determinant of Serum C285 Erythropoietin Level," Blood, 91:2139-45. Chan et al., (1992), "Mechanisms of IFN-γ Induction by Natural Killer Cell Stimulatory Factor (NKSF/IL-12). Role of Transcription and mRNA Stability in the Synergistic Interaction Between NKSF and IL-2," J. Immunol., 148:92-98. Chappel et al., (1991), "Identification of the Fc Gamma Receptor Class I Binding Site In Human IgG Through Use of Recombinant IgG1/IgG2 Hybrid and Point-Mutated Antibodies," Proc. Natl. Acad. Sci. USA, C287 Cheetham, (1998), "NMR Structure of Human Erythropoietin and a Comparison with its Receptor Bound C288 Conformation," Nat. Struct. Biol., 5:861-6. Ciardiello et al., (1996), "Antitumor Activity of Combined Blockade of Epidermal Growth Factor Receptor and C289 Protein Kinase A," J. Natl. Cancer Inst., 88:1770-6. Cirulli et al., (1998), "KSA Antigen Ep-CAM Mediates Cell-Cell Adhesion of Pancreatic Epithelial Cells: C290 Morphoregulatory Roles in Pancreatic Islet Development," J. Cell Biol., 140:1519-34. Cohen et al., (1998), "An Artificial Cell-Cycle Inhibitor Isolated from a Combinatorial Library," Proc. Natl. C291 Acad. Sci. USA, 95:14272-7. Congote et al., (1984), The Erthrotropins, New Erythroid Cell Stimulate Factors Extracted From Human and Bovine Fetal Tissues," Abstract 364, "Proceedings 7th Intl. Congress of Endocrinology," Quebec City, Quebec, July 1-7, 1984.

EXAMINER	DATE CONSIDERED

			Express Mail Mailing Label No.: EV668158635US			
 			. PAGE 5 OF 12			
FORM F	TO - 1	449	ATTORNEY DOCKET NO.: LEX-003			
		AL INFORMATION DISCLOSURE	APPLICANT(S): Gillies et al.			
STATEN	1ENT		SERIAL NO.: 09/256,156			
			FILING DATE: February 24, 1999 GROUP: 1647			
		OTHER ART, JOUR	RNAL ARTICLES, ETC.			
EXAM. INIT.	ОТН	ER DOCUMENTS: (Including Author, Ti	tle, Date, Relevant Pages, Place of Publication)			
	C293	Congote, (1983), "Isolation of Two Biologic Fetal Calf Intestine," <u>Biochem. Biophys. Re</u>	cally Active Peptides, Erythrotropin I and Erythrotropin II from s. Commun., 115(2):477-83.			
	C294	Congote, (1984), "Extraction from Fetal Bor Factor," <u>Anal. Biochem.</u> , 140:428-33.	vine Serum of Erythrotropin, an Erythroid Cell-Stimulating			
	C295		ignment in Human Interleukin-7 by Matrix-Assisted Laser and Site-Directed Cysteine to Serine Mutational Analysis," J. Biol.			
-	C296	Cunningham et al., (1989), "High-Resolutio Scanning Mutagenesis," <u>Science</u> , 244:1081-	n Epitope Mapping of hGH-Receptor Interactions by Alanine- 85.			
	C297	Curiel <i>et al.</i> , (1991), "Adenovirus Enhancement of Transferrin-Polylysine-Mediated Gene Delivery," <u>Proc. Natl. Acad. Sci. USA</u> , 88:8850-4.				
	C298	Dauber-Osguthorpe <i>et al.</i> , (1988), "Structure and Energetics of Ligand Binding to Proteins: Escherichia Coli Dihydrofolate Reductase-Trimethoprim, A Drug-Receptor System," <u>Proteins</u> , 4:31-47.				
•	C299		Reaction Facilities the Cloning, CDR-Grafting, and Rapid dy Directed Against the CD18 Component of Leukocyte Integrins,"			
	C300	De Bruijn et al., (1995), "Phagocyte-Induced Vitro," Eur. J. Immunol., 25:1274-85.	d Antigen-Specific Activation of Unprimed CD8+ T Cells in			
	C301	Delorme et al., (1992), "Role of Glycosylati- Biochemistry, 31:9871-6.	on on the Secretion and Biological Activity of Erythropoietin,"			
	C302	Desai et al., (1992), "IL-12 Receptor. II. Dis 148:3125-32.	tribution and Regulation of Receptor Expression," J. Immunol.,			
	C303	Donnelly et al., (1993), "Targeted Delivery by a Modified Pseudomonas Exotoxin," Pro-	of Peptide Epitopes to Class I Major Histocompatibility Molecules c. Natl. Acad. Sci. USA, 90:3530-4.			
	C304	Donnelly et al., (1997), "DNA Vaccines," A	nnu. Rev. Immunol., 15:617-48.			
	C305	Dube et al., (1988), "Glycosylation at Specific Sites of Erythropoietin is Essential for Biosynthesis, Secretion, and Biological Function," J. Biol. Chem., 263:17516-21.				
	C306	Ellison et al., (1982), "The Nucleotide Seque 10:4071-9.	ence of a Human Immunoglobulin C γ ₁ Gene," <u>Nucleic Acids Res.</u> ,			
	C307	Faas et al., (1993), "Phenotypically Diverse Differentiation Of Hematopoietic Cells," Eu	Mouse Thymic Stromal Cell Lines which Induce Proliferation and r. J. Immunol., 23:1201-14.			
	C308		c C Detection and Function in YT Lymphoid Cells and in the g Factor-Responsive Human Myeloid Cell Line, Tf-1," <u>Blood</u> ,			
	C309	Fawell et al., (1994), "Tat-Mediated Deliver 91:664-8.	y of Heterologous Proteins into Cells," Proc. Natl. Acad. Sci. USA,			

EXAMINER

DATE CONSIDERED

Express Mail Mailing Label No.: EV668158635US PAGE 6 OF 12 FORM PTO - 1449 ATTORNEY DOCKET NO.: LEX-003 APPLICANT(S): Gillies et al. SUPPLEMENTAL INFORMATION DISCLOSURE **STATEMENT** SERIAL NO.: 09/256,156 FILING DATE: February 24, 1999 **GROUP: 1647** OTHER ART, JOURNAL ARTICLES, ETC. EXAM. OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) INIT. Fu et al., (1993), "The Sheep Erythropoietin Gene: Molecular Cloning and Effect of Hemorrhage on Plasma C310 Erythropoietin and Renal/Liver Messenger RNA in Adult Sheep," Mol. Cell. Endocrinol., 93:107-16. Gainsford et al., (1996), "Leptin Can Induce Proliferation, Differentiation, and Functional Activation of C311 Hemopoietic Cells," Proc. Natl. Acad. Sci. USA, 93:14564-14568. Gammon et al., (1992), "Endogenous Loading of HLA-A2 Molecules with an Analog of the Influenza Virus Matrix Protein-Derived Peptide and Its Inhibition By An Exogenous Peptide Antagonist," J. Immunol., 148:7-C312 Ghetie et al., (1990), "Disseminated or Localized Growth of a Human B-Cell Tumor (Daudi) in SCID Mice," C313 Intl. J. Cancer, 45:485. Ghetie et al., (1997), "FcRn: The MHC Class I-Related Receptor that is More Than an IgG Transporter," C314 Immunology Today, 18(12):592-598. Goldwasser et al., (1971), "Purification of Erythropoietin," Proc. Natl. Acad. Sci. USA, 68:697-8. Goldwasser et al., (1975), "Erythropoeitin: Assay and Study of its Mode of Action," Methods Enzymol., C316 37(PtB):109-21. Gurewich et al., (1988), "Characterization of the Intrinsic Fibrinolytic Properties of Pro-Urokinase Through a C317 Study of Plasmin-Resistant Mutant Forms Produced by Site-Specific Mutagenesis of Lysine," J. Clin. Invest., 82:1956-1962. Hashimoto et al., (1999), "Differential Antitumor Effects of Administration of Recombinant IL-18 or Recombinant IL-12 are Mediated Primarily by Fas-Fas Ligand- and Perforin-Induced Tumor Apoptosis, C318 Respectively," J. Immunol., 163:583-9. Henikoff et al., (1992), "Amino Acid Substitution Matrices from Protein Blocks," Proc. Natl. Acad. Sci. USA, C319 89:10915-10919. Hilgers et al., (1999), "Sulfolipo-Cyclodextrin in Squalane-In-Water as a Novel and Safe Vaccine Adjuvant," C320 Vaccine, 17:219-28. Hori et al., (1987), "Establishment of an Interleukin 2-Dependent Human T Cell Line from a Patient with T Cell Chronic Lymphocytic Leukemia Who is Not Infected with Human T Cell Leukemia/Lymphoma Virus," Blood, 70:1069-72. C322 Hulett et al. (1994), "Molecular Basis of Fc Receptor Function," Adv. Immunol., 57:1127. Huston et al., (1988), "Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fv Analogue Produced In Escherichia Coli," Proc. Natl. Acad. Sci. USA, 85:5879-C323

EXAMINER	DATE CONSIDERED

Isaacs et al., (1998), "Therapy with Monoclonal Antibodies. II. The Contribution of Fcy Receptor Binding and

the Influence of CH1 and CH3 Domains on In Vivo Effector Funcion," J. Immunol., 161:3862-3869.

Jacobs et al., (1985), "Isolation and Characterization of Genomic And cDNA Clones of Human

5883.

Erythropoietin," Nature, 313:806-10.

C324

C325

PAGE 7 OF 12

F	ORN	1 P	го	- 14	49				

SUPPLEMENTAL INFORMATION DISCLOSURE **STATEMENT**

ATTORNEY DOCKET NO.: LEX-003

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/256,156

FILING DATE: February 24, 1999 GROUP: 1647

C326 Immunol., 27(12):1237-1240.	OTHER ART, JOURNAL ARTICLES, ETC.						
C327 Karlin et al., (1990), "Methods for Assessing the Statistical Significance of Molecular Sequence Fe Using General Scoring Schemes," Proc. Natl. Acad. Sci. USA, 87:2264-8. C328 Karlin et al., (1993), "Applications and Statistics for Multiple High-Scoring Segments in Molecular Sequences," Proc. Natl. Acad. Sci. USA, 90:5873-7. C329 Karpusas et al., (1997), "The Crystal Structure of Human Interferon β at 2.2-A Resolution," Proc. Natl. Acad. Sci. USA, 94:11813-11818. C330 Kelner et al., (1994), "Lymphotactin: A Cytokine that Represents a New Class of Chemokine," Sci. USA, 94:11813-11818. C331 King et al., (2004), "Phase I Clinical Trial of the Immunocytokine EMD 273063 in Melanoma Patic Clin. Oncol., 22(22):4463-73. C332 Kinman et al., (1997), "Contribution of CpG Motifs to the Immunogenicity of DNA Vaccines," J. 158:3635-9. C333 Ko et al., (2004), "Safety, Pharmacokinetics, and Biological Pharmacodynamics of the Immunocyto 273066 (huKs-IL2)," J. Immunotherapy, 27:232-239. C334 Kuntz et al., (1982), "A Geometric Approach to Macromolecule-Ligand Interactions," J. Mol. Biol. 88. C335 Kurtz, (1982), "A New Candidate for the Regulation of Erythropoiesis. Insulin-Like Growth Factor FEBLAL., 149(1):105-8. C336 Lai et al., (1998), "DNA Vaccines," Crit. Rev. Immunol., 18:449-84. C337 Lai et al., (1993), "Active Immunity against the CD4 Receptor by Using an Antibody Antigenize Residues 41-55 of the First Extracellular Domain," Proc. Natl. Acad. Sci. USA, 90:11683-7. C339 Lanza et al., (1981), "DNA Sequence of a Major Human Erythropoietin Gene," Proc. Natl. Acad. Sci. USA, 78:5435-9. C340 Lin et al., (1985), "Cloning and Expression of the Human Erythropoietin Gene," Proc. Natl. Acad. Sci. USA, 11, 12, 12, 12, 12, 12, 12, 12, 12, 12		ER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)					
Using General Scoring Schemes," Proc. Natl. Acad. Sci. USA, 87:2264-8. C328 Karlin et al., (1993), "Applications and Statistics for Multiple High-Scoring Segments in Molecular Sequences," Proc. Natl. Acad. Sci. USA, 90:5873-7. C329 Karpusas et al., (1997), "The Crystal Structure of Human Interferon β at 2.2-A Resolution," Proc. N Sci. USA, 94:11813-11818. C330 Kelner et al., (1994), "Lymphotactin: A Cytokine that Represents a New Class of Chemokine," Sci. 266:1395-9. C331 King et al., (2004), "Phase I Clinical Trial of the Immunocytokine EMD 273063 in Melanoma Patic Clin. Oncol., 22(22):4463-73. C332 Klinman et al., (1997), "Contribution of CpG Motifs to the Immunogenicity of DNA Vaccines," J. 158:3635-9. C333 Ko et al., (2004), "Safety, Pharmacokinetics, and Biological Pharmacodynamics of the Immunocyto 273066 (huKS-IL2)," J. Immunotherapy, 27:232-239. C334 Kuntz et al., (1982), "A Geometric Approach to Macromolecule-Ligand Interactions," J. Mol. Biol. 88. C335 Kurtz, (1982), "A New Candidate for the Regulation of Erythropoiesis. Insulin-Like Growth Factor EBLAL, 149(1):105-8. C336 Lai et al., (1986), "Structural Characterization of Human Erythropoietin," J. Biol. Chem., 261:3116. C337 Lai et al., (1993), "Active Immunity against the CD4 Receptor by Using an Antibody Antigenize Residues 41-55 of the First Extracellular Domain," Proc. Natl. Acad. Sci. USA, 90:11683-7. C339 Lawn et al., (1981), "DNA Sequence of a Major Human Leukocyte Interferon Gene," Proc. Natl. Acad. Sci. USA, 78:5435-9. C340 Lin et al., (1985), "Cloning and Expression of the Human Erythropoietin Gene," Proc. Natl. Acad. Sci. USA, 78:5435-9.	C326	Jefferis et al., (1990), "Molcular Definition of Interaction Sites on Human IgG for Fc Receptors huFcγR," Mol. Immunol., 27(12):1237-1240.					
Sequences," Proc. Natl. Acad. Sci. USA, 90:5873-7. C329 Karpusas et al., (1997), "The Crystal Structure of Human Interferon β at 2.2-A Resolution," Proc. N. Sci. USA, 94:11813-11818. C330 Kelner et al., (1994), "Lymphotactin: A Cytokine that Represents a New Class of Chemokine," Sci. 266:1395-9. C331 King et al., (2004), "Phase I Clinical Trial of the Immunocytokine EMD 273063 in Melanoma Patic Clin. Oncol., 22(22):4463-73. C332 Klinman et al., (1997), "Contribution of CpG Motifs to the Immunogenicity of DNA Vaccines," J. 158:3635-9. C333 Ko et al., (2004), "Safety, Pharmacokinetics, and Biological Pharmacodynamics of the Immunocyto 273066 (huKS-IL2)," J. Immunotherapy, 27:232-239. C334 Kuntz et al., (1982), "A Geometric Approach to Macromolecule-Ligand Interactions," J. Mol. Biol. 88. C335 Kurtz, (1982), "A New Candidate for the Regulation of Erythropoiesis. Insulin-Like Growth Factor FEBLAL., 149(1):105-8. C336 Lai et al., (1986), "Structural Characterization of Human Erythropoietin," J. Biol. Chem., 261:3116 C337 Lai et al., (1998), "DNA Vaccines," Crit. Rev. Immunol., 18:449-84. C338 Lanza et al., (1993), "Active Immunity against the CD4 Receptor by Using an Antibody Antigenize Residues 41-55 of the First Extracellular Domain," Proc. Natl. Acad. Sci. USA, 90:11683-7. C339 Lawn et al., (1981), "DNA Sequence of a Major Human Leukocyte Interferon Gene," Proc. Natl. Acad. Sci. USA, 78:5435-9. C340 Lin et al., (1985), "Cloning and Expression of the Human Erythropoietin Gene," Proc. Natl. Acad. Sci. 2580-4.	C327	Karlin <i>et al.</i> , (1990), "Methods for Assessing the Statistical Significance of Molecular Sequence Features by Using General Scoring Schemes," <u>Proc. Natl. Acad. Sci. USA</u> , 87:2264-8.					
Sci. USA, 94:11813-11818. C330 Kelner et al., (1994), "Lymphotactin: A Cytokine that Represents a New Class of Chemokine," Sci. 266:1395-9. C331 King et al., (2004), "Phase I Clinical Trial of the Immunocytokine EMD 273063 in Melanoma Patic Clin. Oncol., 22(22):4463-73. Klinman et al., (1997), "Contribution of CpG Motifs to the Immunogenicity of DNA Vaccines," J. 158:3635-9. C332 Ko et al., (2004), "Safety, Pharmacokinetics, and Biological Pharmacodynamics of the Immunocyte 273066 (huKS-IL2)," J. Immunotherapy, 27:232-239. Kuntz et al., (1982), "A Geometric Approach to Macromolecule-Ligand Interactions," J. Mol. Biol. 88. C335 Kurtz, (1982), "A New Candidate for the Regulation of Erythropoiesis. Insulin-Like Growth Factor FEBLAL., 149(1):105-8. C336 Lai et al., (1986), "Structural Characterization of Human Erythropoietin," J. Biol. Chem., 261:3116 C337 Lai et al., (1998), "DNA Vaccines," Crit. Rev. Immunol., 18:449-84. C338 Lanza et al., (1993), "Active Immunity against the CD4 Receptor by Using an Antibody Antigenize Residues 41-55 of the First Extracellular Domain," Proc. Natl. Acad. Sci. USA, 90:11683-7. C339 Lawn et al., (1981), "DNA Sequence of a Major Human Leukocyte Interferon Gene," Proc. Natl. Acad. Sci. USA, 78:5435-9. C340 Lin et al., (1985), "Cloning and Expression of the Human Erythropoietin Gene," Proc. Natl. Acad. Sci. 11 at al., 12 a	C328	Karlin et al., (1993), "Applications and Statistics for Multiple High-Scoring Segments in Molecular Sequences," Proc. Natl. Acad. Sci. USA, 90:5873-7.					
C330 C331 C332 King et al., (2004), "Phase I Clinical Trial of the Immunocytokine EMD 273063 in Melanoma Patic Clin. Oncol., 22(22):4463-73. C332 Klinman et al., (1997), "Contribution of CpG Motifs to the Immunogenicity of DNA Vaccines," J. 158:3635-9. C333 Ko et al., (2004), "Safety, Pharmacokinetics, and Biological Pharmacodynamics of the Immunocyto 273066 (huKs-IL2)," J. Immunotherapy, 27:232-239. C334 Kuntz et al., (1982), "A Geometric Approach to Macromolecule-Ligand Interactions," J. Mol. Biol. 88. C335 Kurtz, (1982), "A New Candidate for the Regulation of Erythropoiesis. Insulin-Like Growth Factor FEBLAL., 149(1):105-8. C336 Lai et al., (1986), "Structural Characterization of Human Erythropoietin," J. Biol. Chem., 261:3116. C337 Lai et al., (1998), "DNA Vaccines," Crit. Rev. Immunol., 18:449-84. C338 C338 C339 Lanza et al., (1993), "Active Immunity against the CD4 Receptor by Using an Antibody Antigenize Residues 41-55 of the First Extracellular Domain," Proc. Natl. Acad. Sci. USA, 90:11683-7. C339 Lawn et al., (1981), "DNA Sequence of a Major Human Leukocyte Interferon Gene," Proc. Natl. Acad. Sci. USA, 78:5435-9. C340 Lin et al., (1985), "Cloning and Expression of the Human Erythropoietin Gene," Proc. Natl. Acad. Sci. 240, 82:7580-4.	C329	Karpusas <i>et al.</i> , (1997), "The Crystal Structure of Human Interferon β at 2.2-A Resolution," <u>Proc. Natl. Acad. Sci. USA</u> , 94:11813-11818.					
Cin. Oncol., 22(22):4463-73. Cin. Oncol., 22(22):4463-73. Klinman et al., (1997), "Contribution of CpG Motifs to the Immunogenicity of DNA Vaccines," J. 158:3635-9. Cin. Ko et al., (2004), "Safety, Pharmacokinetics, and Biological Pharmacodynamics of the Immunocyte 273066 (huKS-IL2)," J. Immunotherapy, 27:232-239. Kuntz et al., (1982), "A Geometric Approach to Macromolecule-Ligand Interactions," J. Mol. Biol. 88. Cin. Kurtz, (1982), "A New Candidate for the Regulation of Erythropoiesis. Insulin-Like Growth Factor FEBLAL., 149(1):105-8. Cin. Cin. Cin. Cin. Cin. Cin. Cin. Cin.	C330	Kelner et al., (1994), "Lymphotactin: A Cytokine that Represents a New Class of Chemokine," Science, 266:1395-9.					
C332 158:3635-9. C333 Ko et al., (2004), "Safety, Pharmacokinetics, and Biological Pharmacodynamics of the Immunocyto 273066 (huKS-IL2)," J. Immunotherapy, 27:232-239. C334 Kuntz et al., (1982), "A Geometric Approach to Macromolecule-Ligand Interactions," J. Mol. Biol. 88. C335 Kurtz, (1982), "A New Candidate for the Regulation of Erythropoiesis. Insulin-Like Growth Factor FEBLAL., 149(1):105-8. C336 Lai et al., (1986), "Structural Characterization of Human Erythropoietin," J. Biol. Chem., 261:3116- C337 Lai et al., (1998), "DNA Vaccines," Crit. Rev. Immunol., 18:449-84. C338 Lanza et al., (1993), "Active Immunity against the CD4 Receptor by Using an Antibody Antigenize Residues 41-55 of the First Extracellular Domain," Proc. Natl. Acad. Sci. USA, 90:11683-7. C339 Lawn et al., (1981), "DNA Sequence of a Major Human Leukocyte Interferon Gene," Proc. Natl. Acad. Sci. USA, 78:5435-9. C340 Lin et al., (1985), "Cloning and Expression of the Human Erythropoietin Gene," Proc. Natl. Acad. Sci. USA, 90:1683-7. Lin et al., (1985), "Cloning and Expression of the Human Erythropoietin Gene," Proc. Natl. Acad. Sci. USA, 90:1683-7.	C331	King et al., (2004), "Phase I Clinical Trial of the Immunocytokine EMD 273063 in Melanoma Patients," <u>J. Clin. Oncol.</u> , 22(22):4463-73.					
C333 273066 (huKS-IL2)," <u>J. Immunotherapy</u> , 27:232-239. C334 Kuntz et al., (1982), "A Geometric Approach to Macromolecule-Ligand Interactions," <u>J. Mol. Biol.</u> 88. C335 Kurtz, (1982), "A New Candidate for the Regulation of Erythropoiesis. Insulin-Like Growth Factor FEBLAL., 149(1):105-8. C336 Lai et al., (1986), "Structural Characterization of Human Erythropoietin," <u>J. Biol. Chem.</u> , 261:3116- C337 Lai et al., (1998), "DNA Vaccines," <u>Crit. Rev. Immunol.</u> , 18:449-84. C338 Lanza et al., (1993), "Active Immunity against the CD4 Receptor by Using an Antibody Antigenize Residues 41-55 of the First Extracellular Domain," <u>Proc. Natl. Acad. Sci. USA</u> , 90:11683-7. C339 Lawn et al., (1981), "DNA Sequence of a Major Human Leukocyte Interferon Gene," <u>Proc. Natl. Acad. Sci. USA</u> , 78:5435-9. C340 Lin et al., (1985), "Cloning and Expression of the Human Erythropoietin Gene," <u>Proc. Natl. Acad. Sci. 1987</u> , 1985, "Cloning and Expression of the Human Erythropoietin Gene," <u>Proc. Natl. Acad. Sci. 1987</u> , 1985, "Cloning and Expression of the Human Erythropoietin Gene," <u>Proc. Natl. Acad. Sci. 1987</u> , 1985, "Cloning and Expression of the Human Erythropoietin Gene," <u>Proc. Natl. Acad. Sci. 1987</u> , 1985, "Cloning and Expression of the Human Erythropoietin Gene," <u>Proc. Natl. Acad. Sci. 1987</u> , 1985, "Cloning and Expression of the Human Erythropoietin Gene," <u>Proc. Natl. Acad. Sci. 1987</u> , 1985, "Cloning Expression and Comparison with the Human Erythropoietin Gene," <u>Proc. Natl. Acad. Sci. 1987</u> , 1985, "Cloning Expression and Comparison with the Human Erythropoietin Gene."	C332	Klinman et al., (1997), "Contribution of CpG Motifs to the Immunogenicity of DNA Vaccines," J. Immunol., 158:3635-9.					
C334 88. C335 Kurtz, (1982), "A New Candidate for the Regulation of Erythropoiesis. Insulin-Like Growth Factor FEBLAL., 149(1):105-8. C336 Lai et al., (1986), "Structural Characterization of Human Erythropoietin," J. Biol. Chem., 261:3116- C337 Lai et al., (1998), "DNA Vaccines," Crit. Rev. Immunol., 18:449-84. C338 Lanza et al., (1993), "Active Immunity against the CD4 Receptor by Using an Antibody Antigenize Residues 41-55 of the First Extracellular Domain," Proc. Natl. Acad. Sci. USA, 90:11683-7. C339 Lawn et al., (1981), "DNA Sequence of a Major Human Leukocyte Interferon Gene," Proc. Natl. Acad. Sci. USA, 78:5435-9. C340 Lin et al., (1985), "Cloning and Expression of the Human Erythropoietin Gene," Proc. Natl. Acad. Sci. USA, 90:11683-7.	C333	Ko et al., (2004), "Safety, Pharmacokinetics, and Biological Pharmacodynamics of the Immunocytokine EMD 273066 (huKS-IL2)," J. Immunotherapy, 27:232-239.					
C336 Lai et al., (1986), "Structural Characterization of Human Erythropoietin," J. Biol. Chem., 261:3116. C337 Lai et al., (1998), "DNA Vaccines," Crit. Rev. Immunol., 18:449-84. C338 Lanza et al., (1993), "Active Immunity against the CD4 Receptor by Using an Antibody Antigenize Residues 41-55 of the First Extracellular Domain," Proc. Natl. Acad. Sci. USA, 90:11683-7. C339 Lawn et al., (1981), "DNA Sequence of a Major Human Leukocyte Interferon Gene," Proc. Natl. Acad. Sci. USA, 78:5435-9. C340 Lin et al., (1985), "Cloning and Expression of the Human Erythropoietin Gene," Proc. Natl. Acad. Sci. USA, 82:7580-4.	C334	Kuntz et al., (1982), "A Geometric Approach to Macromolecule-Ligand Interactions," J. Mol. Biol., 161:269-88.					
C337 Lai et al., (1998), "DNA Vaccines," Crit. Rev. Immunol., 18:449-84. C338 Lanza et al., (1993), "Active Immunity against the CD4 Receptor by Using an Antibody Antigenize Residues 41-55 of the First Extracellular Domain," Proc. Natl. Acad. Sci. USA, 90:11683-7. C339 Lawn et al., (1981), "DNA Sequence of a Major Human Leukocyte Interferon Gene," Proc. Natl. Acad. Sci. USA, 78:5435-9. C340 Lin et al., (1985), "Cloning and Expression of the Human Erythropoietin Gene," Proc. Natl. Acad. Sci. USA, 78:5435-9. Lin et al., (1986), "Monkey Erythropoietin Gene: Cloning Expression and Comparison with the Human Erythropoietin Gene," Proc. Natl. Acad. Sci. USA, 78:5435-9.	C335	Kurtz, (1982), "A New Candidate for the Regulation of Erythropoiesis. Insulin-Like Growth Factor I," FEBLAL., 149(1):105-8.					
C338 Lanza et al., (1993), "Active Immunity against the CD4 Receptor by Using an Antibody Antigenize Residues 41-55 of the First Extracellular Domain," Proc. Natl. Acad. Sci. USA, 90:11683-7. C339 Lawn et al., (1981), "DNA Sequence of a Major Human Leukocyte Interferon Gene," Proc. Natl. Acad. Sci. USA, 78:5435-9. C340 Lin et al., (1985), "Cloning and Expression of the Human Erythropoietin Gene," Proc. Natl. Acad. Sci. USA, 78:5435-9. Lin et al., (1986), "Monkey Erythropoietin Gene: Cloning, Expression and Comparison with the Human Erythropoietin Gene," Proc. Natl. Acad. Sci. USA, 78:5435-9.	C336	Lai et al., (1986), "Structural Characterization of Human Erythropoietin," J. Biol. Chem., 261:3116-21.					
C338 Residues 41-55 of the First Extracellular Domain," Proc. Natl. Acad. Sci. USA, 90:11683-7. Lawn et al., (1981), "DNA Sequence of a Major Human Leukocyte Interferon Gene," Proc. Natl. Acad. Sci. USA, 78:5435-9. Lin et al., (1985), "Cloning and Expression of the Human Erythropoietin Gene," Proc. Natl. Acad. Sci. USA, 78:5435-9. Lin et al., (1986), "Monkey Erythropoietin Gene: Cloning, Expression and Comparison with the Human Erythropoietin Gene," Proc. Natl. Acad. Sci. USA, 90:11683-7.	C337	Lai et al., (1998), "DNA Vaccines," Crit. Rev. Immunol., 18:449-84.					
USA, 78:5435-9. Lin et al., (1985), "Cloning and Expression of the Human Erythropoietin Gene," Proc. Natl. Acad. S 82:7580-4. Lin et al. (1986) "Monkey Erythropoietin Gene: Cloning Expression and Comparison with the Hu	C338	Lanza et al., (1993), "Active Immunity against the CD4 Receptor by Using an Antibody Antigenized with Residues 41-55 of the First Extracellular Domain," Proc. Natl. Acad. Sci. USA, 90:11683-7.					
82:7580-4. Linet al. (1986) "Mankey Frythropoietin Gene: Cloning Expression and Comparison with the Hu	C339	Lawn et al., (1981), "DNA Sequence of a Major Human Leukocyte Interferon Gene," Proc. Natl. Acad. Sci. USA, 78:5435-9.					
Lin et al., (1986), "Monkey Erythropoietin Gene: Cloning, Expression and Comparison with the Hu	C340	Lin et al., (1985), "Cloning and Expression of the Human Erythropoietin Gene," Proc. Natl. Acad. Sci. USA, 82:7580-4.					
Erythropoietin Gene," Gene, 44:201-9.	C341	Lin et al., (1986), "Monkey Erythropoietin Gene: Cloning, Expression and Comparison with the Human Erythropoietin Gene," Gene, 44:201-9.					
	C342						

EXAMINER

DATE CONSIDERED

PAGE 8 OF 12

ATTORNEY DOCKET NO.: LEX-003 FORM PTO - 1449 APPLICANT(S): Gillies et al. SUPPLEMENTAL INFORMATION DISCLOSURE **STATEMENT** SERIAL NO.: 09/256,156 FILING DATE: February 24, 1999 GROUP: 1647 OTHER ART, JOURNAL ARTICLES, ETC. EXAM. OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) INIT. Lorenz et al., (1999), "Induction of Anti-Tumor Immunity Elicited by Tumor Cells Expressing a Murine LFA-C343 3 Analog Via a Recombinant Vaccinia Virus," Hum. Gene Ther., 10:623-31. Lotze et al., (1996), "Cytokine Gene Therapy of Cancer Using Interleukin-12; Murine and Clinical Trials," C344 Ann. NY Acad. Sci., 795:440-54. Macdougall et al., (1999), "Pharmacokinetics of Novel Erythropoiesis Stimulating Protein Compared with C345 Epoetin Alfa in Dialysis Patients," J. Am. Soc. Nephrol., 10:2392-5. MacLean et al., (1996), "Enhancing the Effect of Theratope STn-KLH Cancer Vaccine in Patients with Metastatic Breast Cancer by Pretreatment with Low-Dose Intravenous Cyclophosphamide," J. Immunother., C346 19(4):309-316. Maghazachi et al., (1997), "Interferon-Inducible Protein-10 and Lymphotactin Induce the Chemotaxis and Mobilization of Intracellular Calcium in Natural Killer Cells through Pertussis Toxin-Sensitive and -Insensitive C347 Heterotrimeric G-Proteins," FASEB J., 11:765-74. Mariani et al., (1997), "Tumor Targeting Potential of the Monoclonal Antibody BC-1 against Oncofetal C348 Fibronectin in Nude Mice Bearing Human Tumor Implants," Cancer, 80:2378-84. Marshall et al., (1994), "Role of the Polymorphic Residues in HLA-DR Molecules in Allele-Specific Binding C349 of Peptide Ligands," J. Immunol., 152:4946-57. Marshall et al., (1995), "Prediction of Peptide Affinity to HLA-DR Molecules," Biomed. Pept. Proteins C350 Nucleic Acids, 1(3):157-62. McDonald, (1986), "Cloning, Sequencing, and Evolutionary Analysis of the Mouse Erythropoietin Gene," Mol. C351 Cell. Biol., 6:842-8. McGonigle et al., (1984), "Erythropoietin Deficiency and Inhibition of Erythropoiesis in Renal Insufficiency," C352 Kidney Int., 25(2):437-44. McMahan et al., (1991), "A Novel IL-1 Receptor, Cloned From B-Cells by Mammalian Expression is C353 Expressed in Many Cell Types," EMBO J., 10:2821-32. McMahon et al., (1990), "Pharmacokinetics and Effects of Recombinant Human Erythropojetin after C354 Intravenous and Subcutaneous Injections in Healthy Volunteers," Blood, 76:1718-22 Mehrotra et al., (1993), "Effects of IL-12 on the Generation of Cytotoxic Activity in Human CD8+ T C355 Lymphocytes," J. Immunol., 151:2444-52. Menard et al., (1983), "Generation of Monoclonal Antibodies Reacting with Normal and Cancer Cells of C356 Human Breast," Cancer Res., 43:1295-300. Miyake et al., (1977), "Purification of Human Erythropoietin," J. Biol. Chem., 252:558-64. C357 Miyake et al., (1988), "Synthesis of Recombinant Human Single-Chain Urokinase-Type Plasminogen C358 Activator Variants Resistant to Plasmin and Thrombin," J. Biochem., 104:643-647.

EXAMINER	DATE CONSIDERED

			Express Mail Mailing Label No.: EV668158635US
			PAGE 9 OF 12
FORM PTO - 1449		449	ATTORNEY DOCKET NO.: LEX-003
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		AL INFORMATION DISCLOSURE	APPLICANT(S): Gillies et al.
			SERIAL NO.: 09/256,156
·			FILING DATE: February 24, 1999 GROUP: 1647
		OTHER ART, JOU	RNAL ARTICLES, ETC.
EXAM. INIT.	ОТН	ER DOCUMENTS: (Including Author, Ti	tle, Date, Relevant Pages, Place of Publication)
	C359	Morrison et al., (1984), "Chimeric Human A Constant Region Domains," Proc. Natl. Aca	Antibody Molecules: Mouse Antigen-Binding Domains with Human ad. Sci. USA, 81:6851-5.
	C360	Nagao et al., (1992), "Nucleotide Sequence	of Rat Erythropoietin," <u>Biochim. Biophys. Acta</u> , 1171(1):99-102.
	C361	Nastala et al., (1994), "Recombinant IL-12 γ Production," J. Immunol., 153:1697-706.	Administration Induces Tumor Regression in Association with IFN-
	C362 Naughton <i>et al.</i> , (1983), "Evidence for an Erythropoietin-Stimulating Factor in Patients with Renal and Her Disease," <u>Acta. Haemat.</u> , 69:171-9.		rythropoietin-Stimulating Factor in Patients with Renal and Hepatic
	C363 Neal et al., (2004), "Enhanced Activity of Hu14.18-IL2 Immunocytokine against Murine NXS2 Neuroblaste when Combined with Interleukin-2 Therapy," Clin. Cancer. Res., 10:4839-4847. C364 Nelles et al., (1987), "Characterization of Recombinant Human Single Chain Urokinase-Type Plaminogen Activtor Mutants Produced by Site-Specific Mutagenesis of Lysine 158," J. Biol. Chem., 262(12):5682-568		
C365 Noguchi <i>et al.</i> , (1994), "A Mouse Mutant P53 Product Recognized by CD4+ and CD8+ T Cells," Product Recognized by CD4+ and CD8+ T Cells, "Product Recognized by CD4+ and CD8+ T Cells," Product Recognized by CD4+ and CD8+ T Cells, "Product Recognized by CD4+ and CD8+ T Cells," Product Recognized by CD4+ and CD8+ T Cells, "Product Recognized by CD4+ and CD8+ T Cells," Product Recognized by CD4+ and CD8+ T Cells, "Product Recognized by CD4+ and CD8+ T Cells," Product Recognized by CD4+ and CD8+ T Cells, "Product Recognized by CD4+ and CD8+ T Cells," Product Recognized by CD4+ and CD8+ T Cells, "Product Recognized by CD4+ and CD8+ T Cells," Product Recognized by CD4+ and CD8+ T Cells, "Product Recognized by CD4+ and CD8+ T Cells," Product Recognized by CD4+ and CD8+ T Cells, "Product Recognized by CD4+ and CD8+ T Cells," Product Recognized by CD4+ and CD8+ T Cells, "Product Recognized by CD4+ and CD8+ T Cells," Product Recognized by CD4+ and CD8+ T Cells, "Product Recognized by CD4+ and CD8+ T Cells," Product Recognized by CD4+ and CD8+ T Cells," Product Recognized by CD4+ and CD8+ T Cells," Product Recognize		53 Product Recognized by CD4+ and CD8+ T Cells," Proc. Natl.	
	C366 Orlandi et al., (1989), "Cloning Immunoglobulin Variable Domains for Expression by the Polymerase C Reaction," Proc. Natl. Acad. Sci. USA, 86:3833-7. C367 Palucka et al., (1998), "Dendritic Cells as the Terminal Stage of Monocyte Differentiation," J. Immunol. 160:4587-95. C368 Panina-Bordignon et al., (1989), "Universally Immunogenic T Cell Epitopes: Promiscuous Binding to Him MHC Class II and Promiscuous Recognition by T Cells," Eur. J. Immunol., 19:2237-42		* · · · · · · · · · · · · · · · · · · ·
			ne Terminal Stage of Monocyte Differentiation," J. Immunol.,
	C369		Prostaglandin Synthetase Inhibitors, Salt Overload and Stimulated Erythropoietin Production in Rats," Exp. Hematol.,
	C370	Pedley et al. (1999), "Enhancement of Antib by an Antivascular Agent," <u>Cancer Res.</u> , 59:	pody-Directed Enzyme Prodrug Therapy in Colorectal Xenografts :3998-4003.
	C371		Cell Stimulatory Factor or IL-12 Has Differential Effects on the phocytes, and NK Cells," J. Immunol., 149:3495-502.
	C372	Pluschke et al., (1996), "Molecular Cloning Proteoglycan," Proc. Natl. Acad. Sci. USA,	of a Human Melanoma-Associated Chondroitin Sulfate 93:9710-5.
	C373	Poon et al., (1995), "Structure and Function Interchanges Between Human IgM and Mou	of Several Anti-Dansyl Chimeric Antibodies Formed by Domain use IgG2b," J. Biol. Chem., 270:8571-7.
	C374	Queen <i>et al.</i> , (1989), "A Humanized Antiboo <u>USA</u> , 86:10029-33.	dy that Binds to the Interleukin 2 Receptor," Proc. Natl. Acad. Sci.
	C375	Radhakrishnan et al., (1996), "Zinc Mediated Crystallography," Structure 4(12):1453-63.	d Dimer of Human Interferon-α _{2b} Revealed by X-Ray

EXAMINER DATE CONSIDERED

PAGE 10 OF 12

FORM PTO - 1449 ATTORNEY DOCKET NO.: LEX-003 SUPPLEMENTAL INFORMATION DISCLOSURE APPLICANT(S): Gillies et al. **STATEMENT** SERIAL NO.: 09/256,156 **GROUP: 1647** FILING DATE: February 24, 1999 OTHER ART, JOURNAL ARTICLES, ETC. EXAM. OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) INIT. C376 Ramachandran et al., (1968) "Conformation of Polypeptides and Proteins," Adv. Prot. Chem., 23:283-299. Rarey et al., (1995), "Time-Efficient Docking of Flexible Ligands into Active Sites Of Proteins," Proc. Int. C377 Conf. Intell. Syst. Mol. Biol. 3:300-8. Resegotti et al., (1981), "Treatment of Aplastic Anaemia with Methenolone, Stanozolol and Nandrolone. A C378 Report of 130 Cases," Pan. Med., 23:243-8. C379 Riechmann et al., (1988), "Reshaping Human Antibodies for Therapy," Nature, 332:323-7. Robinson et al., (1998), "Optimizing the Stability of Single-Chain Proteins by Linker Length and Composition C380 Mutagenesis," Proc. Natl. Acad. Sci. USA, 95:5929-34. Rothmann et al., (1982), "Erythropoietin-Dependent Erythrocytosis associated with Hepatic Angiosarcoma," J. C381 Surg. Oncol., 20:105-8. Runkel et al., (1998), "Structural and Functional Differences Between Glycosylated and Non-Glycosylated C382 Forms of Human Interferon-B (IFN-B)," Pharmaceutical Res., 15:641-649. Sakano et al., (1980), "Two Types of Somatic Recombination are Necessary for the Generation of Complete C383 Immunoglobin Heavy-Chain Genes," Nature, 286:676-683. Săli et al., (1993), "Comparative Protein Modelling by Satisfaction of Spatial Restraints," J. Mol. Biol., C384 234:779-815. Schecter et al., (1997), "Tissue Factor is Induced by Monocyte Chemoattractant Protein-1 in Human Aortic C385 Smooth Muscle And THP-1 Cells," J. Biol. Chem., 272:28568-73. Sharp et al., (1988), "Codon Usage Patterns in Escherichia coli, Bacillus subtilis, Saccharomyces cerevisiae, C386 Schizosaccharomyces pombe, Drosophila melanogaster and Homo sapiens; a Review of the Consdierable Within-Species Diversity," Nucleic Acids Res., 16(17):8207-8211. Simonsen et al., (1983), "Isolation and Expression of an Altered Mouse Dihydrofolate Reductase cDNA," Proc. C387 Natl. Acad. Sci. USA, 80:2495-2499. Smith et al., (1981), "Identification of Common Molecular Subsequences," J. Mol. Biol., 147:195-197. C388 Soligo et al., (1998), "Expansion of Dendritic Cells Derived from Human CD34+ Cells in Static And C389 Continuous Perfusion Cultures," Br. J. Haematol., 101:352-63. Spivak et al., (1989), "The In Vivo Metabolism of Recombinant Human Erythropoietin in The Rat," Blood, C390 73:90-9. Sturniolo et al., (1999), "Generation of Tissue-Specific and Promiscuous HLA Ligand Databases Using DNA C391 Microarrays and Virtual HLA Class II Matrices," Nat. Biotech., 17(6):555-61. Suliman et al., (1996), "Cloning of a cDNA Encoding Bovine Erythropoietin and Analysis of Its Transcription C392 in Selected Tissues," Gene, 171:275-80.

EXAMINER	DATE CONSIDERED

PAGE 11 OF 12 ATTORNEY DOCKET NO.: LEX-003 **FORM PTO - 1449** SUPPLEMENTAL INFORMATION DISCLOSURE APPLICANT(S): Gillies et al. STATEMENT SERIAL NO.: 09/256,156 FILING DATE: February 24, 1999 **GROUP: 1647** OTHER ART, JOURNAL ARTICLES, ETC. EXAM. OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) INIT. Taniguchi et al., (1980), "Expression of the Human Fibroblast Interferon Gene in Escherichia Coli," Proc. Natl. C393 Acad. Sci. USA, 77:5230-5233. Thurner, (1999), "Generation of Large Numbers of Fully Mature and Stable Dendritic Cells from C394 Leukapheresis Products for Clinical Application," J. Immunol. Methods, 223:1-15. Tiruppathi et al., (1996), "Isolation and Characterization of a Cell Surface Albumin-Binding Protein from C395 Vascular Endothelial Cells," Proc. Nat. Acad. Sci. USA, 93:250-4. Van Den Eynde et al., (1989), "Presence on a Human Melanoma of Multiple Antigens Recognized By C396 Autologous CTL," Int. J. Cancer, 44:634-40. Van Der Bruggen et al., (1991), "A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a C397 Human Melanoma," Science, 254:1643-7 Van Heyningen et al., (1982), "Human MHC Class II Molecules as Differentiation Markers," Immunogenetics, C398 C399 Voest et al., (1995), "Inhibition of Angiogenesis in Vivo by Interleukin 12," J. Natl. Canc. Inst., 87:581-6. Von Heijne et al., (1986), "A New Method for Predicting Signal Sequence Cleavage Sites," Nucleic Acid Res., C400 14:4683-4690. Ward et al., (1995), "The Effector Functions of Immunoglobulins: Implications for Therapy," Therapeutic. C401 Immunology, 2:77-94. C402 Watson et al., (1984), "Compilation of Published Signal Sequences," Nucleic Acid Res., 12:5145-5164. Weber et al., (2001), "Phase I Trial of huKS-IL2 Immunocytokine in Patients with Prostate Carcinoma: C403 Clinical, PK, and Biological PD Results (Abstract)," American Society of Clinical Oncology Program/Proceedings, 20(Part 1):259a. Weitkamp et al., (1973), "Additional Data on the Population Distribution of Human Serum Albumin Genes; C404 Three New Variants," Ann. Hum. Genet., 37:219-26. Woof et al., (1986), "Localisation of the Monocyte-Binding Region on Human Immunoglobulin G," Mol. C405 Immunol., 23:319-30. Wyatt et al., (1998), "The Antigenic Structure of the HIV gp120 Envelope Glycoprotein," Nature, 393:705-11. C406 Wysocka et al., (1995), "Interleukin-12 is Required for Interferon-y Production and Lethality in C407 Lipopolysaccharide-Induced Shock in Mice," Eur. J. Immunol., 25:672-6.

	EXAMINER	 DATE CONSIDERED	
1	EARMINER	DATE CONSIDERED	

Increased Avidity for Antigen," J. Immunol., 157:1582-8.

C408

C409

Yan et al., (1996), "Characterization of an Ig VH Idiotope that Results in Specific Homophilic Binding and

Antiviral Properties of a Serum Albumin-CD4 Genetic Conjugate," Proc. Natl. Acad. Sci. USA, 89:1904-8.

Yeh et al., (1992), "Design of Yeast-Secreted Albumin Derivatives for Human Therapy: Biological and

PAGE 12 OF 12

FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT			ATTORNEY DOCKET NO.: LEX-003 APPLICANT(S): Gillies et al. SERIAL NO.: 09/256,156 FILING DATE: February 24, 1999 GROUP: 1647	
	OTHER ART, JOURNAL ARTICLES, ETC.			
EXAM. INIT.				
	C410 Zhang et al., (1994), "Structure/Activity Analysis of Human Monocyte Chemoattractant Protein-1 (MCP-1) by Mutagenesis," J. Biol. Chem., 269:15918-24.			
	C411	Zuckier et al., (1998), "Chimeric Human-Mouse IgG Antibodies with Shuffled Constant Region Exons Demonstrate that Multiple Domains Contribute to In Vivo Half-Life," Cancer Res., 58(17):3905-8.		
EXAMINER DATE CONSIDERED		DATE CONSIDERED		

BOS-818730 v1